Drugs / JCAR014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02706405 | Nov 2016 → May 2021 | high-grade B-cell lymphoma double-hit/triple-hit, primary mediastinal large B-cell lymphoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCAR014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02706405 ↗ |
| Action | Deplete | “which programs them to kill lymphoma cells.” NCT02706405 ↗ |
| Modality | Cell therapy | “JCAR014 is made of each patient's immune cells (T cells) that have a new gene added to them in a laboratory” NCT02706405 ↗ |
| Route | Intravenous | “Given IV” NCT02706405 ↗ |
| Target | CD19 | “anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014)” NCT02706405 ↗ |